FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164973558> ?p ?o ?g. }

• W3164973558 abstract "Otomycosis is a fungal infection of the outer ear, which may be treated with topical antifungal medications. There are many types, with compounds belonging to the azole group ('azoles') being among the most widely used.To evaluate the benefits and harms of topical azole treatments for otomycosis.The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The search date was 11 November 2020.We included randomised controlled trials (RCTs) in adults and children with otomycosis comparing any topical azole antifungal with: placebo, no treatment, another type of topical azole or the same type of azole but applied in different forms. A minimum follow-up of two weeks was required.We used standard Cochrane methods. Our primary outcomes were: 1) clinical resolution as measured by the proportion of participants with complete resolution at between two and four weeks after treatment (however defined by the authors of the studies) and 2) significant adverse events. Secondary outcomes were 3) mycological resolution and 4) other less serious adverse effects. We used GRADE to assess the certainty of evidence for each outcome.We included four studies with 559 participants from Spain, Mexico and India. Three studies included children and adults; one included only adults. The duration of symptoms was not always explicitly stated. Mycological resolution results were only reported in one study. The studies assessed two comparisons: one type of topical azole versus another and the same azole but administered in different forms (cream versus solution). A. Topical azoles versus placebo None of the studies assessed this comparison. B. Topical azoles versus no treatment None of the studies assessed this comparison. C. One type of topical azole versus another type of topical azole i) Clotrimazole versus other types of azoles (eberconazole, fluconazole, miconazole) Three studies examined clotrimazole versus other types of azoles. The evidence is very uncertain about the difference between clotrimazole and other types of azole in achieving complete clinical resolution at four weeks (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.59 to 1.07; 3 studies; 439 participants; very low-certainty evidence). The anticipated absolute effects are 668 per 1000 for clotrimazole versus 835 per 1000 for other azoles. One study planned a safety analysis and reported no significant adverse events in either group. The evidence is therefore very uncertain about any differences between clotrimazole and other types of azole (no events in either group; 1 study; 174 participants; very low-certainty evidence). Clotrimazole may result in little or no difference in mycological resolution at two weeks follow-up (RR 1.01, 95% CI 0.96 to 1.06; 1 study; 174 participants; low-certainty evidence) or in other (less serious) adverse events at two weeks follow-up (36 per 1000, compared to 45 per 1000, RR 0.79, 95% CI 0.18 to 3.41; 1 study; 174 participants; very low-certainty evidence). ii) Bifonazole cream versus bifonazole solution One study compared bifonazole 1% cream with solution. Bifonazole cream may have little or no effect on clinical resolution at two weeks follow-up when compared to solution, but the evidence is very uncertain (RR 1.07, 95% CI 0.73 to 1.57; 1 study; 40 ears; very low-certainty evidence). Bifonazole cream may achieve less mycological resolution compared to solution at two weeks after the end of therapy, but the evidence for this is also very uncertain (RR 0.53, 95% CI 0.29 to 0.96; 1 study; 40 ears; very low-certainty evidence). Five out of 35 patients sustained severe itching and burning from the bifonazole solution but none with the bifonazole cream (very low-certainty evidence).We found no studies that evaluated topical azoles compared to placebo or no treatment. The evidence is very uncertain about the effect of clotrimazole on clinical resolution of otomycosis, on significant adverse events or other (non-serious) adverse events when compared with other topical azoles (eberconazole, fluconazole, miconazole). There may be little or no difference between clotrimazole and other azoles in terms of mycological resolution. It may be difficult to generalise these results because the range of ethnic backgrounds of the participants in the studies is limited." @default.
• W3164973558 created "2021-06-07" @default.
• W3164973558 creator A5028242361 @default.
• W3164973558 creator A5089417828 @default.
• W3164973558 creator A5091560530 @default.
• W3164973558 date "2021-05-25" @default.
• W3164973558 modified "2023-10-01" @default.
• W3164973558 title "Topical azole treatments for otomycosis" @default.
• W3164973558 cites W1512571721 @default.
• W3164973558 cites W1874527066 @default.
• W3164973558 cites W1977796523 @default.
• W3164973558 cites W1980188678 @default.
• W3164973558 cites W2006790824 @default.
• W3164973558 cites W2025360026 @default.
• W3164973558 cites W2035054483 @default.
• W3164973558 cites W2042939315 @default.
• W3164973558 cites W2044139486 @default.
• W3164973558 cites W2044472829 @default.
• W3164973558 cites W2044863379 @default.
• W3164973558 cites W2052385457 @default.
• W3164973558 cites W2071426657 @default.
• W3164973558 cites W2075146827 @default.
• W3164973558 cites W2095184838 @default.
• W3164973558 cites W2108696783 @default.
• W3164973558 cites W2110147016 @default.
• W3164973558 cites W2123134253 @default.
• W3164973558 cites W2149647565 @default.
• W3164973558 cites W2157428610 @default.
• W3164973558 cites W2158069073 @default.
• W3164973558 cites W2172635720 @default.
• W3164973558 cites W2266344952 @default.
• W3164973558 cites W2412597392 @default.
• W3164973558 cites W2414028404 @default.
• W3164973558 cites W2418841338 @default.
• W3164973558 cites W2442178663 @default.
• W3164973558 cites W2463293493 @default.
• W3164973558 cites W2463402361 @default.
• W3164973558 cites W2485668586 @default.
• W3164973558 cites W2610561184 @default.
• W3164973558 cites W2793376745 @default.
• W3164973558 cites W2809004855 @default.
• W3164973558 cites W2809044723 @default.
• W3164973558 cites W2890212216 @default.
• W3164973558 cites W2915244600 @default.
• W3164973558 cites W2952669835 @default.
• W3164973558 cites W3011091120 @default.
• W3164973558 cites W3024449214 @default.
• W3164973558 cites W3149064888 @default.
• W3164973558 cites W4236805817 @default.
• W3164973558 cites W4254817215 @default.
• W3164973558 cites W4290664135 @default.
• W3164973558 cites W4300591273 @default.
• W3164973558 cites W64256106 @default.
• W3164973558 doi "https://doi.org/10.1002/14651858.cd009289.pub2" @default.
• W3164973558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8147581" @default.
• W3164973558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34033120" @default.
• W3164973558 hasPublicationYear "2021" @default.
• W3164973558 type Work @default.
• W3164973558 sameAs 3164973558 @default.
• W3164973558 citedByCount "4" @default.
• W3164973558 countsByYear W31649735582021 @default.
• W3164973558 countsByYear W31649735582022 @default.
• W3164973558 countsByYear W31649735582023 @default.
• W3164973558 crossrefType "journal-article" @default.
• W3164973558 hasAuthorship W3164973558A5028242361 @default.
• W3164973558 hasAuthorship W3164973558A5089417828 @default.
• W3164973558 hasAuthorship W3164973558A5091560530 @default.
• W3164973558 hasBestOaLocation W31649735582 @default.
• W3164973558 hasConcept C126322002 @default.
• W3164973558 hasConcept C142724271 @default.
• W3164973558 hasConcept C16005928 @default.
• W3164973558 hasConcept C168563851 @default.
• W3164973558 hasConcept C17744445 @default.
• W3164973558 hasConcept C187212893 @default.
• W3164973558 hasConcept C197934379 @default.
• W3164973558 hasConcept C199539241 @default.
• W3164973558 hasConcept C204787440 @default.
• W3164973558 hasConcept C27081682 @default.
• W3164973558 hasConcept C2779473830 @default.
• W3164973558 hasConcept C2779548794 @default.
• W3164973558 hasConcept C2780315139 @default.
• W3164973558 hasConcept C2780651595 @default.
• W3164973558 hasConcept C535046627 @default.
• W3164973558 hasConcept C71924100 @default.
• W3164973558 hasConcept C95190672 @default.
• W3164973558 hasConceptScore W3164973558C126322002 @default.
• W3164973558 hasConceptScore W3164973558C142724271 @default.
• W3164973558 hasConceptScore W3164973558C16005928 @default.
• W3164973558 hasConceptScore W3164973558C168563851 @default.
• W3164973558 hasConceptScore W3164973558C17744445 @default.
• W3164973558 hasConceptScore W3164973558C187212893 @default.
• W3164973558 hasConceptScore W3164973558C197934379 @default.
• W3164973558 hasConceptScore W3164973558C199539241 @default.
• W3164973558 hasConceptScore W3164973558C204787440 @default.
• W3164973558 hasConceptScore W3164973558C27081682 @default.
• W3164973558 hasConceptScore W3164973558C2779473830 @default.
• W3164973558 hasConceptScore W3164973558C2779548794 @default.
• W3164973558 hasConceptScore W3164973558C2780315139 @default.
• W3164973558 hasConceptScore W3164973558C2780651595 @default.
• W3164973558 hasConceptScore W3164973558C535046627 @default.

• next